CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
2015; Elsevier BV; Volume: 126; Issue: 6 Linguagem: Inglês
10.1182/blood-2015-02-628669
ISSN1528-0020
AutoresPatrick R. Hagner, Hon‐Wah Man, Celia Fontanillo, Maria Wang, Suzana Couto, Mike A. Breider, Chad C. Bjorklund, Courtney G. Havens, Gang Lu, Emily Rychak, Heather K. Raymon, Rama Krishna Narla, Leo A. Barnes, Gody Khambatta, Hsiling Chiu, Jolanta Kosek, Jian Kang, Michael D. Amantangelo, Michelle F. Waldman, Antonia López-Girona, Ti Cai, Michael Pourdehnad, Matthew Trotter, Thomas O. Daniel, Peter Schäfer, Anke Klippel, Anjan Thakurta, Rajesh Chopra, Anita K. Gandhi,
Tópico(s)CAR-T cell therapy research
ResumoKey Points CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity. CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL.
Referência(s)